BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 33002832)

  • 1. CRISPR/Cas9 editing to generate a heterozygous COL2A1 p.G1170S human chondrodysplasia iPSC line, MCRIi019-A-2, in a control iPSC line, MCRIi019-A.
    Kung LHW; Sampurno L; Yammine KM; Graham A; McDonald P; Bateman JF; Shoulders MD; Lamandé SR
    Stem Cell Res; 2020 Oct; 48():101962. PubMed ID: 33002832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of a heterozygous COL2A1 (p.G1113C) hypochondrogenesis mutation iPSC line, MCRIi019-A-7, using CRISPR/Cas9 gene editing.
    Lilianty J; Bateman JF; Lamandé SR
    Stem Cell Res; 2021 Oct; 56():102515. PubMed ID: 34543885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using CRISPR/Cas9 to generate a heterozygous COL2A1 p.R719C iPSC line (MCRIi019-A-6) model of human precocious osteoarthritis.
    Yammine KM; Mirda Abularach S; Sampurno L; Bateman JF; Lamandé SR; Shoulders MD
    Stem Cell Res; 2023 Mar; 67():103020. PubMed ID: 36682125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of a heterozygous COL2A1 (p.R989C) spondyloepiphyseal dysplasia congenita mutation iPSC line, MCRIi001-B, using CRISPR/Cas9 gene editing.
    Lilianty J; Nur Patria Y; Stanley EG; Elefanty AG; Bateman JF; Lamandé SR
    Stem Cell Res; 2020 May; 45():101843. PubMed ID: 32446218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR/Cas9 gene editing of a SOX9 reporter human iPSC line to produce two TRPV4 patient heterozygous missense mutant iPSC lines, MCRIi001-A-3 (TRPV4 p.F273L) and MCRIi001-A-4 (TRPV4 p.P799L).
    Nur Patria Y; Stenta T; Lilianty J; Rowley L; Stanley EG; Elefanty AG; Bateman JF; Lamandé SR
    Stem Cell Res; 2020 Oct; 48():101942. PubMed ID: 32771907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of a gene corrected human isogenic iPSC line (CPGHi002-A-1) from a DDOD patient with heterozygous c.1516 C>T mutation in the ATP6V1B2 gene.
    Gao X; Qiu SW; Wang WQ; Kang DY; Su N; Dai P; Yuan YY
    Stem Cell Res; 2021 May; 53():102271. PubMed ID: 33714068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determining the Pathogenicity of a Genomic Variant of Uncertain Significance Using CRISPR/Cas9 and Human-Induced Pluripotent Stem Cells.
    Ma N; Zhang JZ; Itzhaki I; Zhang SL; Chen H; Haddad F; Kitani T; Wilson KD; Tian L; Shrestha R; Wu H; Lam CK; Sayed N; Wu JC
    Circulation; 2018 Dec; 138(23):2666-2681. PubMed ID: 29914921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generating an iPSC line (with isogenic control) from the PBMCs of an ACTA1 (p.Gly148Asp) nemaline myopathy patient.
    Houweling PJ; Coles CA; Tiong CF; Nielsen B; Graham A; McDonald P; Suter A; Piers AT; Forbes R; Ryan MM; Howden SE; Lamandé SR; North KN
    Stem Cell Res; 2021 Jul; 54():102429. PubMed ID: 34157503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of a gene corrected human isogenic IBMS-iPSC-014-C from polycystic-kidney-disease induced pluripotent stem cell line using CRISPR/Cas9.
    Liu CL; Huang CY; Chen HC; Lu HE; Hsieh PCH; Lee JJ
    Stem Cell Res; 2020 May; 45():101784. PubMed ID: 32361310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of a heterozygous COL1A1 (c.3969_3970insT) osteogenesis imperfecta mutation human iPSC line, MCRIi001-A-1, using CRISPR/Cas9 editing.
    Hosseini Far H; Patria YN; Motazedian A; Elefanty AG; Stanley EG; Lamandé SR; Bateman JF
    Stem Cell Res; 2019 May; 37():101449. PubMed ID: 31075690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of a human Neurochondrin deficient iPSC line KICRi002-A-3 using CRISPR/Cas9.
    Fatima A; Schuster J; Akram T; Sobol M; Hoeber J; Dahl N
    Stem Cell Res; 2020 Apr; 44():101758. PubMed ID: 32203915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction of Hirschsprung-Associated Mutations in Human Induced Pluripotent Stem Cells Via Clustered Regularly Interspaced Short Palindromic Repeats/Cas9, Restores Neural Crest Cell Function.
    Lai FP; Lau ST; Wong JK; Gui H; Wang RX; Zhou T; Lai WH; Tse HF; Tam PK; Garcia-Barcelo MM; Ngan ES
    Gastroenterology; 2017 Jul; 153(1):139-153.e8. PubMed ID: 28342760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of an induced pluripotent stem cell line from a patient with global development delay carrying DYRK1A mutation (c.1730T>A) and a gene correction isogenic iPSC line.
    Ma L; Wu Z; Tang Q; Ji X; Mei Y; Peng T; Xu Q; Zhou W; Xiong M
    Stem Cell Res; 2021 May; 53():102305. PubMed ID: 33813175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of two ISL1-tdTomato reporter human induced pluripotent stem cell lines using CRISPR-Cas9 genome editing.
    Tsukamoto S; Nakade K; Wakabayashi T; Nakashima K; Takami M; Hemmi Y; Kuramochi Y; Shimizu T; Arai Y; Matsuo-Takasaki M; Noguchi M; Nakamura Y; Miwa Y; Hayashi Y
    Stem Cell Res; 2021 May; 53():102363. PubMed ID: 34087992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene Editing in Human Induced Pluripotent Stem Cells Using Doxycycline-Inducible CRISPR-Cas9 System.
    Thamodaran V; Rani S; Velayudhan SR
    Methods Mol Biol; 2022; 2454():755-773. PubMed ID: 33830454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR/Cas9 Genome Editing: A Promising Tool for Therapeutic Applications of Induced Pluripotent Stem Cells.
    Zhang Y; Sastre D; Wang F
    Curr Stem Cell Res Ther; 2018; 13(4):243-251. PubMed ID: 29446747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of simultaneous reprogramming and gene correction to generate an osteogenesis imperfecta patient COL1A1 c. 3936 G>T iPSC line and an isogenic control iPSC line.
    Howden S; Hosseini Far H; Motazedian A; Elefanty AG; Stanley EG; Lamandé SR; Bateman JF
    Stem Cell Res; 2019 Jul; 38():101453. PubMed ID: 31082677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of a gene-corrected isogenic iPSC line (AHQUi001-A-1) from a patient with familial hypertriglyceridemia (FHTG) carrying a heterozygous p.C310R (c.928 T > C) mutation in LPL gene using CRISPR/Cas9.
    Sun X; Zhou X; Dong B; Wang C; Xiao X; Wang Y
    Stem Cell Res; 2021 Apr; 52():102230. PubMed ID: 33592566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of heterozygous (MRli003-A-3) and homozygous (MRli003-A-4) TRPM4 knockout human iPSC lines.
    Zhang F; Meier AB; Lipp P; Laugwitz KL; Dorn T; Moretti A
    Stem Cell Res; 2022 Apr; 60():102731. PubMed ID: 35245852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
    Doetschman T; Georgieva T
    Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.